Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 7/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479835 | 1.00 | IAPP (0.54) | IAPPPTGS1APPGLATDP1 | |
| SCHEMBL28529134 | 0.86 | IAPP (0.54) | IAPPPTGS1APPGLATDP1 | |
| SCHEMBL29373808 | 0.86 | IAPP (0.54) | IAPPPTGS1APPGLATDP1 | |
| SCHEMBL13858839 | 0.84 | PYGL (0.45) | TDP1KCNA3PYGLPTGS2 | |
| SCHEMBL13858840 | 0.84 | PYGL (0.45) | TDP1KCNA3PYGLPTGS2 | |
| SCHEMBL1344144 | 0.84 | KDM4E (0.53) | APPGLATDP1KCNA3PYGL | |
| SCHEMBL1344147 | 0.84 | KDM4E (0.53) | APPGLATDP1KCNA3PYGL | |
| SCHEMBL556337 | 0.84 | IAPP (0.59) | IAPPPTGS1APPGLATDP1 | |
| SCHEMBL1344557 | 0.84 | PYGL (0.60) | IAPPPTGS1APPGLATDP1 | |
| SCHEMBL1344558 | 0.84 | PYGL (0.60) | IAPPPTGS1APPGLATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | IAPP 1199/4885PTGS1 1012/4885APP 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.